SEC Form 4 · accession 0001140361-18-021843
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Pendarvis
Officer — Chief Administrative Officer
Period of report
May 3, 2018
Accepted (ET)
May 4, 2018 · 8:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | May 3, 2018 | M | 2,810 | $38.98 | A | 98,043 | D | |
| ResMed Common Stock | May 3, 2018 | S | 2,810 | $95.91 | D | 95,233 | D | |
| ResMed Common Stock | May 3, 2018 | M | 1,951 | $51.25 | A | 97,184 | D | |
| ResMed Common Stock | May 3, 2018 | M | 1,922 | $52.02 | A | 99,106 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock OptionsF2 | $38.98 | May 3, 2018 | M | 2,810 | D | Nov 11, 2013 | Nov 15, 2019 | ResMed Common Stock | 2,810 | 16,860 | D |
| ResMed Common Stock OptionsF3 | $51.25 | May 3, 2018 | M | 1,951 | D | Nov 13, 2016 | Nov 13, 2020 | ResMed Common Stock | 1,951 | 0 | D |
| ResMed Common Stock OptionsF3 | $52.02 | May 3, 2018 | M | 1,922 | D | Nov 11, 2017 | Nov 19, 2021 | ResMed Common Stock | 1,922 | 0 | D |
Explanation of responses
- F1The transaction was conducted under a Rule 10b5-1 plan.
- F2Represents date options first became exercisable. Options vest 1/3 per year.
- F3Represents date options first became exercisable. ISO options vested on the third anniversary of the grant.